Ensuring Compliance for In Vitro Diagnostic (IVD) Devices
In Vitro Diagnostic (IVD) devices are essential for accurate disease detection and monitoring. Due to their impact on patient health, they must meet strict regulatory requirements to ensure safety and effectiveness.
In Vitro Diagnostic (IVD) devices — including diagnostic test kits, analysers, reagents, calibrators, control materials, and diagnostic software used to examine specimens derived from the human body — must satisfy strict regulatory requirements before reaching the market. In the EU, compliance is governed by IVDR 2017/746; in the UK by the UK IVDR; and in the US by FDA regulations under 21 CFR Part 820 and applicable guidance documents.
In Vitro Diagnostic (IVD) devices are essential for accurate disease detection and monitoring. Due to their impact on patient health, they must meet strict regulatory requirements to ensure safety and effectiveness.
Why IVD Compliance Matters
Regulatory bodies like the FDA (U.S.), IVDR (EU), and MHRA (UK) set rigorous standards to protect public health. Non-compliance can lead to market rejections, legal issues, and reputational risks.
Key Compliance Areas
- Device Classification & Risk Assessment – Determines the applicable regulatory pathway.
- Regulatory Approvals – Includes FDA 510(k), PMA, De Novo, and EU IVDR compliance.
- Performance Evaluation – Clinical and analytical studies ensure accuracy and reliability.
- Quality Management System (QMS) – ISO 13485 certification for consistent quality.
- Labeling & Post-Market Surveillance – Ensures continued compliance and patient safety.
How Advena Medical Can Help
At Advena Medical, we simplify the regulatory process, guiding IVD manufacturers through approvals and compliance requirements.
Our Services Include:
- Regulatory strategy & risk assessment
- FDA & IVDR submission support
- Clinical study guidance
- ISO 13485 QMS implementation
- Post-market compliance & reporting
Let’s Get Started
Avoid delays and compliance pitfalls. Contact Advena Today to ensure your IVD device meets global standards seamlessly.
Frequently Asked Questions
What classifies a product as an In Vitro Diagnostic device?
An IVD is any medical device — including reagents, reagent products, kits, instruments, equipment, or software — intended by the manufacturer for use in examining specimens derived from the human body for purposes such as disease diagnosis, monitoring of physiological conditions, or determination of safety or compatibility with potential recipients. This definition covers a wide range from simple lateral flow tests to complex automated analyser platforms.
Do IVD devices need clinical performance studies under IVDR?
Yes. IVDR requires manufacturers to demonstrate clinical performance — the ability of a device to yield clinically meaningful results — through clinical performance studies or scientific literature review. The extent of evidence required depends on classification: Class D (highest risk, e.g. blood group typing, HIV tests) requires the most rigorous evidence, while Class A devices have lighter requirements.
What is a Unique Device Identification (UDI) for IVD devices?
UDI is a series of numeric or alphanumeric characters created through a globally accepted device identification and coding standard that allows the unambiguous identification of a specific device on the market. Under IVDR, UDI labelling and registration in the EUDAMED database is mandatory and is being phased in by device class from 2023 onwards.
What are the IVDR compliance timelines for legacy IVD devices?
IVDs with valid IVDD Notified Body certificates may continue on the market until: 26 May 2025 for Class D devices; 26 May 2026 for Class C; and 26 May 2027 for Class B and Class A sterile devices — provided the manufacturer has a QMS in place and a formal request to a Notified Body submitted by May 2024.